Bank of America Securities released a research report stating that SKB BIO-B's (06990) core asset SKB264 has achieved steady progress across multiple indications. The firm has increased the success probability for its clinical-stage indications, thereby raising peak sales estimates for corresponding indications, and has raised this year's collaboration revenue forecast based on the company's interim results. Bank of America Securities raised its target price for SKB BIO-B from HK$340 to HK$471.5, believing that the asset's clinical progress meets expectations. The firm raised the company's revenue forecasts for this year through 2027 by 1% to 6%, and adjusted full-year gross margin forecasts based on interim profit margins. Based on the company's better-than-expected operational efficiency, the firm lowered its estimates for the company's sales expenses and R&D expenses from this year through 2027.